Join our daily newsletter At The Bell to receive exclusive market insights
- Proteomics International Laboratories (PIQ) intends to apply for a U.S. reimbursement code for its diabetic kidney disease test
- It follows an economic assessment by Boston Healthcare Associates of PIQ’s patented PromarkerD test, compared to the current standard of care
- The modelling showed PromarkerD could generate savings of US$862 million (approximately A$1.1 billion) over four years per million patients tested, primarily derived from slowing the progression of the disease
- PIQ has been trading 3.85 per cent higher at $1.08
Proteomics International Laboratories (PIQ) intends to apply for a CPT proprietary laboratory analysis reimbursement code for its PromarkerD test.
It follows an economic assessment by Boston Healthcare Associates of PIQ’s patented diabetic kidney disease test, compared to the current standard of care.
The modelling showed PromarkerD could generate net savings for payers of US$862 million (approximately A$1.1 billion) over four years per million Type 2 diabetic patients tested, primarily derived from slowing the progression of the disease.
“With PromarkerD testing, patients may delay or avoid costly end outcomes such as dialysis and kidney transplants,” said PIQ Managing Director Dr Richard Lipscombe.
“Given there are approximately 31 million diabetics in the United States alone, the economic benefit of PromarkerD is clearly evident.”
The company and Boston Healthcare will present the modelling at the Professional Society for Health Economics and Outcomes Research’s annual conference next week.
PIQ has been trading 3.85 per cent higher at $1.08 at 10:06 am AEST.
